Zitelmi 40 Tablet contains Telmisartan 40 mg, an angiotensin II receptor antagonist used primarily for the management of hypertension. By selectively blocking the binding of angiotensin II to the AT1 receptor, Telmisartan promotes vasodilation, thereby reducing peripheral vascular resistance and lowering blood pressure. This mechanism helps to prevent complications associated with hypertension such as stroke, myocardial infarction, and renal impairment. Zitelmi 40 is indicated for the treatment of essential hypertension and may be prescribed alone or in combination with other antihypertensive agents to achieve optimal blood pressure control. The tablet is typically administered once daily, with or without food, and dosage adjustments should be based on clinical response and tolerability. It is contraindicated in patients with hypersensitivity to Telmisartan or any component of the formulation, and caution is advised in individuals with severe hepatic impairment, bilateral renal artery stenosis, or during pregnancy. Common adverse effects include dizziness, headache, and fatigue, while serious side effects are rare but may include renal dysfunction and hyperkalemia. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy with Zitelmi 40 to ensure safety and efficacy.